This is especially true for those dealing with hormonal belly fat
Sanz-Cuesta T, Gonzlez-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-Gonzlez I, Martn-Fernndez J, Escortell-Mayor E, Rodrguez-Salvans F, Garca-Solano M, Gonzlez-Gonzlez R, Martn-de la Sierra M
But, this research doesnt look at compounded versions, so its too soon to tell if the same benefits apply
Other documented GI effects include constipation , diarrhea , bloating , and appetite changes
Approval Expectation: Under "Fast Track" or "Priority Review" designations often given to breakthrough metabolic therapies, an FDA approval decision is anticipated in late 2026 or early 2027
Nauck MA, Quast DR (2021) Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6